阿里将医药板块统一整合，交由阿里健康统筹

作者：亿邦动力文章来源：亿邦动力

2026-05-15 16:40

作者：亿邦动力文章来源：亿邦动力

2026-05-15 16:40

邦小白快读

全文速览

本文核心信息围绕阿里巴巴整合集团医药板块业务，以及阿里健康最新业绩、战略布局展开，核心干货如下

1. 组织调整：阿里成立医药业务专项小组，将B2C、O2O闪购的人事、汇报关系完全打通，全部交由阿里健康统一指挥。这是阿里10年间第四次给阿里健康注入业务资源，本次是组织架构层面的最高权限支持

2. 业绩情况：阿里健康近三个财年营收和净利润持续增长，2026财年业绩创近五年新高，实现营收342.55亿元，同比增长12%，净利润19.36亿元，同比增长35.2%

3. 业务布局：阿里健康已经推出首个医学AI产品“氢离子”，正式确立“医药全栈+医学AI”双轮驱动战略，目前平台商家数、SKU、用户规模均保持高速增长，多个业务板块都在快速扩张。

本次阿里整合医药板块的动作，给医药品牌商传递了明确的行业变化和业务机会，核心干货如下

1. 行业与消费趋势：医药电商赛道集中度进一步提升，头部平台话语权持续增强。目前线上医药市场仍在快速扩容，天猫健康有交易商家数同比增长26%，处方药业务、慢病管理服务增长明显，自营会员ARPU同比增长超14%，用户付费需求持续提升

2. 商业合作机会：阿里健康的码上放心平台已经构建了覆盖全产业链的药品流通网络，已经和1300多家头部药企达成深度合作，可提供数字化营销、渠道库存管理、流向管理、患者教育等多元化服务

3. 布局参考：整合后平台组织协同性大幅提升，品牌商可对接统一的平台接口获得更稳定的流量支持，同时要关注头部集中后赛道竞争格局的变化，调整自身的线上布局策略。

本次阿里医药板块整合，给医药线上卖家带来了明确的机会和需要关注的变化，核心干货如下

1. 增长机会：阿里整合内部医药业务后，B2C和O2O闪购业务实现组织层面完全打通，卖家可以获得更统一的流量和运营支持。目前赛道仍处于增长阶段，天猫健康有交易商家数、SKU均保持25%以上的增速，新老卖家都仍有拓店扩容的空间

2. 方向提示：当前处方药、慢病管理相关类目保持高速增长，用户付费能力持续提升，卖家可以重点布局这类高增长赛道，匹配用户需求获得更多增长红利

3. 风险提示：本次整合消息公布后，阿里健康股价短期出现超4%的跌幅，卖家需要关注后续平台的政策调整，提前适配新组织架构下的运营规则，做好应对变化的准备。

本次阿里医药板块整合，对医药生产工厂来说，有明确的商业机会和数字化转型参考，核心干货如下

1. 商业机会：阿里健康整合后头部平台的优势进一步放大，其搭建的码上放心追溯平台已经覆盖4600余家生产企业、12000多家流通企业、80万家医药零售终端，已经吸引1300多家头部药企深度合作，医药生产工厂均可申请接入该平台，对接全渠道流通网络

2. 数字化转型启示：阿里健康已经实现了医药全链路数字化，工厂可以依托平台的“一物一码”数据能力，完成流向管理、库存管理的数字化升级，还能借助平台直接触达终端和C端用户，开展数字化营销和患者教育

3. 生产需求参考：线上医药市场的SKU快速增长，处方药和慢病相关产品需求增长明显，工厂在产品研发和生产规划阶段，可以适当向这类热门需求倾斜，对接线上市场的增长红利。

本次阿里整合医药板块，反映了医药互联网行业的最新发展趋势，也给医疗健康相关服务商指明了方向，核心干货如下

1. 行业发展趋势：医药互联网行业正在走向头部集中，头部平台正在打通B2C、O2O等全渠道业务，从单一的电商交易服务，向“医药全栈服务+医学AI技术”双轮驱动转型，全产业链的数字化需求在持续提升

2. 客户痛点梳理：当前医药产业链上下游都存在未被满足的数字化需求，生产企业需要全链路追溯、渠道库存管理能力，药企需要患者运营和数字化营销服务，医生需要专业工具解决临床科研问题，这些都是服务商的机会点

3. 发展方向参考：头部平台已经搭建了完善的底层生态，服务商可以围绕平台整合后的需求，对接平台生态，聚焦细分领域提供专业服务，共同完善医药数字化的产业链布局，获得更多业务机会。

本次阿里健康整合医药板块的动作，给其他医药健康平台提供了多维度的参考，核心干货如下

1. 行业需求变化：当前市场对医药线上全渠道协同的需求明显提升，商家和用户都希望获得统一的服务体验，打通B2C和O2O全渠道、整合分散业务是行业的明确发展趋势

2. 运营管理参考：阿里健康通过持续注入业务、整合组织的方式，实现了连续三年营收和利润双增长，通过推出医学AI产品开辟第二增长曲线，通过搭建追溯生态服务B端药企，通过扩张专业服务团队完善C端健康服务，这些策略都可供同类型平台参考

3. 风向规避提示：本次整合消息公布后，阿里健康股价短期出现明显下跌，说明资本市场对整合效果仍持观望态度，平台推进大型组织整合时，需要做好市场预期管理，提前完成业务衔接，避免对业绩和市场信心造成负面影响。

本次阿里整合医药板块的动作，反映了国内医药互联网产业的最新动向，对产业研究有较高的参考价值，核心干货如下

1. 产业新动向：国内医药互联网行业已经从早期的分散布局走向头部集中，头部互联网集团正在将分散的医药业务整合，交由专业旗舰平台统一运营，头部效应不断强化，行业目前已经形成“交易+服务+技术”的新发展方向，阿里健康“医药全栈+医学AI”双轮驱动就是典型的新模式

2. 商业模式创新：头部医药互联网平台不再只依赖电商交易佣金和自营收入，已经拓展出数字化追溯服务、药企数字化营销服务、医学AI服务等多元盈利点，本次阿里健康收购阿里妈妈医疗营销业务，预计每年可新增10亿以上营收，证明多元盈利模式的可行性

3. 研究数据支撑：本文公开了阿里健康连续三个财年的营收、利润数据，以及各业务板块的商家、用户、产业链覆盖等详细数据，为研究国内医药互联网产业发展提供了一手的真实数据支撑。

声明：快读内容全程由AI生成，请注意甄别信息。如您发现问题，请发送邮件至 run@ebrun.com 。

我是品牌商卖家工厂服务商平台商研究者帮我再读一遍。

Quick Summary

This article centers on Alibaba Group's consolidation of its pharmaceutical business segment, along with AliHealth's latest financial performance and strategic positioning. Key takeaways are as follows:

1. Organizational restructuring: Alibaba has established a special working group for its pharmaceutical business, fully integrating the personnel and reporting lines of its B2C and O2O flash sale operations, and placing all business under the unified management of AliHealth. This is the fourth time in 10 years that Alibaba has injected business resources into AliHealth, and this round marks the highest level of organizational support through structural overhaul.

2. Financial performance: AliHealth has posted consecutive revenue and net profit growth over the past three fiscal years. In fiscal year 2026, it hit a five-year high with revenue of RMB 34.255 billion, up 12% year-over-year, and net profit of RMB 1.936 billion, up 35.2% year-over-year.

3. Business expansion: AliHealth has launched Qingli Zi, its first medical AI product, and formally adopted a "full-stack pharmaceutical services + medical AI" dual-engine growth strategy. Currently, the number of platform merchants, SKUs, and user size are all growing at a fast clip, with multiple business segments expanding rapidly.

Alibaba's consolidation of its pharmaceutical segment sends clear signals of industry change and new business opportunities for pharmaceutical brands. Key insights are as follows:

1. Industry and consumer trends: The online pharmaceutical e-commerce track is seeing further consolidation, with leading platforms continuously gaining greater market power. The online pharmaceutical market is still expanding rapidly: the number of active trading merchants on Tmall Health grew 26% year-over-year, prescription drug and chronic disease management services posted notable growth, and the average ARPU of self-operated platform members increased more than 14% year-over-year, reflecting sustained growth in user willingness to pay.

2. Business collaboration opportunities: AliHealth's Trusted Code platform has built a pharmaceutical distribution network covering the entire industrial chain, and established in-depth partnerships with more than 1,300 leading pharmaceutical companies. It offers a full suite of diversified services including digital marketing, channel inventory management, distribution flow management, and patient education.

3. Strategic positioning reference: After consolidation, the platform's organizational coordination has improved significantly. Brands can access a unified platform interface for more stable traffic support, while also needing to adjust their online positioning strategies to account for the changed competitive landscape amid ongoing industry consolidation.

Alibaba's pharmaceutical business consolidation brings clear opportunities and key changes for online pharmaceutical sellers. Key takeaways are as follows:

1. Growth opportunities: Following the internal integration of Alibaba's pharmaceutical business, B2C and O2O flash sale operations have been fully aligned at the organizational level, allowing sellers to access more unified traffic and operational support. The track is still in a growth phase: the number of active merchants and SKUs on Tmall Health both grow at over 25% annually, leaving room for both new and existing sellers to expand their store footprint and business scale.

2. Direction guidance: Prescription drugs and chronic disease management-related categories maintain high growth rates, alongside continuous improvement in user purchasing power. Sellers can prioritize these high-growth segments to align with user demand and capture greater growth dividends.

3. Risk reminder: After the consolidation announcement, AliHealth's share price dropped more than 4% in the short term. Sellers should monitor upcoming platform policy adjustments, adapt early to operational rules under the new organizational structure, and prepare for upcoming changes.

Alibaba's pharmaceutical business consolidation brings clear commercial opportunities and digital transformation references for pharmaceutical manufacturing factories. Key insights are as follows:

1. Commercial opportunities: Post-consolidation, the leading platform's competitive advantages have been further amplified. Its Trusted Code traceability platform already covers more than 4,600 manufacturing enterprises, over 12,000 distribution companies, and 800,000 pharmaceutical retail terminals, and has attracted more than 1,300 leading pharmaceutical companies for in-depth collaboration. All pharmaceutical manufacturing factories can apply to access the platform and connect to its omni-channel distribution network.

2. Digital transformation insights: AliHealth has achieved full-link digitization for the pharmaceutical industry. Factories can leverage the platform's "one-code-one-product" data capability to complete digital upgrades for distribution flow and inventory management, and can also directly reach terminals and end consumers via the platform to carry out digital marketing and patient education.

3. Production planning reference: With the rapid growth of SKUs in the online pharmaceutical market, demand for prescription drugs and chronic disease-related products is growing notably. Factories can appropriately shift R&D and production capacity toward these high-demand categories to capture growth dividends from the online market.

Alibaba's consolidation of its pharmaceutical segment reflects the latest development trends of the online pharmaceutical industry, and points out clear development directions for healthcare-related service providers. Key takeaways are as follows:

1. Industry development trends: The online pharmaceutical industry is consolidating around leading players, who are integrating B2C, O2O and other omni-channel operations. The industry is shifting from pure e-commerce transaction services to a "full-stack pharmaceutical services + medical AI technology" dual-driven growth model, and demand for full-industrial-chain digitization continues to rise.

2. Unmet client pain points: There remains unmet demand for digitization across the pharmaceutical industry chain: manufacturing enterprises need full-link traceability and channel inventory management capabilities, pharmaceutical companies need patient operations and digital marketing services, and clinicians need professional tools to support clinical research. All of these represent untapped opportunities for service providers.

3. Development direction reference: Leading platforms have already built a complete underlying ecosystem. Service providers can align with the new needs that emerge from platform consolidation, access the platform ecosystem, focus on niche segments to deliver specialized services, jointly improve the industrial layout of pharmaceutical digitization, and capture more business opportunities.

AliHealth's consolidation of the pharmaceutical segment provides multi-dimensional references for other pharmaceutical and healthcare platforms. Key insights are as follows:

1. Changing industry demand: Market demand for unified omni-channel online pharmaceutical services has increased notably, as both merchants and users expect a consistent service experience. Integrating fragmented B2C and O2O operations and unifying scattered businesses is a clear industry trend.

2. Operations management reference: AliHealth has achieved three consecutive years of double growth in revenue and profit through continuously injecting business resources and integrating organizational structures, opened up a second growth curve by launching medical AI products, served B-side pharmaceutical companies by building a traceability ecosystem, and expanded professional service teams to improve C-side health services. All of these strategies offer valuable references for peer platforms.

3. Risk mitigation guidance: After the consolidation announcement, AliHealth's share price fell notably in the short term, indicating capital markets remain cautious about the outcome of the integration. When rolling out large-scale organizational consolidation, platforms need to manage market expectations, complete business handover in advance, and avoid negative impacts on financial performance and market confidence.

Alibaba's consolidation of its pharmaceutical segment reflects the latest developments in China's online pharmaceutical industry, and offers high reference value for industrial research. Key takeaways are as follows:

1. New industrial trends: China's online pharmaceutical industry has shifted from early fragmented布局 to concentration around leading players. Large internet groups are integrating scattered pharmaceutical businesses and placing them under the unified operation of a professional flagship platform, continuously strengthening the head effect. The industry has now formed a new development direction of "transaction + services + technology", and AliHealth's "full-stack pharmaceuticals + medical AI" dual-driven model is a typical example of this new pattern.

2. Business model innovation: Leading online pharmaceutical platforms are no longer solely reliant on e-commerce transaction commissions and self-operated revenue; they have expanded into diversified profit streams including digital traceability services, digital marketing services for pharmaceutical companies, and medical AI services. AliHealth's recent acquisition of Alimama's healthcare marketing business is expected to add more than RMB 1 billion in annual revenue, proving the viability of this diversified profit model.

3. Research data support: This article publishes AliHealth's three consecutive fiscal years of revenue and profit data, as well as detailed data on the number of merchants, user scale, and industrial chain coverage across business segments, providing first-hand real data to support research on the development of China's online pharmaceutical industry.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】5月15日消息，今天上午，阿里健康召开2026财年财报分析师电话会议上，阿里健康董事会主席兼CEO沈涤凡透露，阿里巴巴将统一整合集团内的医药板块业务，交由阿里健康统筹，以便紧密协同，形成合力。

具体来说，阿里巴巴在集团内部成立了一个医药业务专项小组，将B2C和O2O闪购在组织人事和汇报关系层面完全打通，该小组由阿里健康统一指挥。

阿里健康是阿里巴巴集团在医疗健康领域的旗舰级平台。过去10年，阿里巴巴曾4次向阿里健康注入成熟业务资产，帮助其快速扩充其业务版图和营收。

2017年至2020年期间，阿里巴巴分3次向阿里健康注入资产，实质均为天猫体系下医药类目的“自营收入+平台佣金”。2023年，阿里健康又以135亿港元的对价，收购阿里妈妈医疗健康业务的独家营销审核权及营销增值服务经营权，预计每年为阿里健康带来10亿以上的营收。

而这一次，阿里巴巴直接在组织架构上给予了阿里健康最高权限的支持。

5月14日，阿里健康发布2026财年业绩公告。公告显示：截至2026年3月31日，阿里健康实现营收342.55亿元，同比增长12%；净利润19.36亿元，同比增长35.2%；调整后净利润达23.26亿元，同比增长19.3%。

报告期内，阿里健康首个医学AI产品“氢离子”正式上线，定位为一款“可靠的医学AI助手”。该产品旨在“顶级医学证据”“循证医学”“AI能力”三个维度，直连国内外顶刊的最高证据源，帮助中国医生解决临床与科研中的医学问题。“氢离子”的发布标志着阿里健康正式确立“医药全栈+医学AI”双轮驱动的新战略布局。

公告显示：天猫健康平台服务的在线主营商家数和有交易商家数均保持高速增长，其中有交易商家数同比增长26%达4.75万个。天猫健康平台在线有交易SKUs增长25.8%至2750万个，阿里健康大药房SKUs增长79%至220万个。自营店处方药业务保持高速增长，年度活跃用户数和自营会员数量持续提升，自营会员ARPU同比增长超过14%。得益于不断扩大的平台规模以及极高的用户黏性，阿里健康的领先优势愈发明显。

医疗健康服务方面，阿里健康加速构建“药企—平台—医患”三方协同的数字化患者服务生态。截至2026年3月31日，与阿里健康签约提供在线健康咨询服务的执业医师、执业药师和营养师合计增长至近27万；同时，阿里健康不断提升慢病用户体验，累计慢病支付用户数同比增长23%，人均DOT时长同比持续增长。

在数字化追溯业务方面，码上放心平台通过药品全流程追溯体系及首营资料、检验报告电子化流转，构建一张覆盖4600余家生产企业、12000多家流通企业、80万家医药零售终端的药品流通网络。基于该药品流通网络和“一物一码”数据能力，阿里健康已与1300多家头部药企达成深度合作关系，持续为药企提供数字化营销、渠道管理、流向管理、库存管理、患者教育等数字化服务。

根据阿里健康发布的年度业绩公告，公司近三个财年营收与净利润持续增长。FY2024（截至2024年3月31日），阿里健康实现营业收入270.27亿元，归母净利润8.83亿元，营收增速放缓至0.98%，但净利润同比大幅增长64.93%。FY2025，公司营收增至305.98亿元，同比增长13.22%，归母净利润达14.32亿元，同比增长62.13%。FY2026，公司业绩创近五年新高，营收达342.55亿元，同比增长11.95%，归母净利润为19.36亿元，同比增长35.17%。

5月15日开盘后股价下挫。早盘低开0.22%，盘中最低触及4.21港元，跌幅一度达7.27%。截至午间收盘，股价报4.25港元，跌约6.4%。收盘阶段跌幅略有收窄至4%左右。

亿邦持续追踪报道该情报，如想了解更多与本文相关信息，请扫码关注作者微信。

【版权提示】亿邦动力倡导尊重与保护知识产权。未经许可，任何人不得复制、转载、或以其他方式使用本网站的内容。如发现本站文章存在版权问题，烦请提供版权疑问、身份证明、版权证明、联系方式等发邮件至run@ebrun.com，我们将及时沟通与处理。

已点赞

好文章,值得被更多人看到

FAQ回顾

阿里巴巴如何整合其医药板块业务？

阿里巴巴在集团内部成立医药业务专项小组，将B2C和O2O闪购在组织人事和汇报关系上完全打通，并由阿里健康统一指挥，实现业务统筹。

阿里健康2026财年的业绩表现如何？

截至2026年3月31日，阿里健康实现营收342.55亿元，同比增长12%；净利润19.36亿元，同比增长35.2%。其首个医学AI产品“氢离子”也正式上线。

阿里健康在数字化患者服务和药品追溯方面有哪些进展？

阿里健康签约近27万执业医师、药师和营养师提供在线咨询，慢病支付用户数增长23%。其“码上放心”平台覆盖超4600家生产企业，并与1300多家药企达成深度合作。

标签:: 未来零售

日薪120元全民数采谁在训练下一个机器人保姆？

亿邦AI深度调研了当下具身智能数据采集的现状，既期待与技术脉搏同频，也期待看到普通人分享行业红利。

独家

2026-05-15 16:37:59